• Something wrong with this record ?

The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms

I. Borbath, R. Garcia-Carbonero, D. Bikmukhametov, P. Jimenez-Fonseca, A. Castaño, J. Barkmanova, E. Sedlackova, A. Kollár, E. Christ, G. Kaltsas, B. Kos-Kudla, S. Maasberg, C. Verslype, UF. Pape

. 2022 ; 168 (-) : 80-90. [pub] 20220423

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018156

BACKGROUND: Neuroendocrine neoplasms (NENs) are rare tumours with variable clinical behaviour. Their natural history is ideally best approached in large, multicentre and multinational registries with long-term patients' follow-up. The European Neuroendocrine Tumour Society registry aims to obtain information regarding NEN outcomes and prognostic factors in a European frame. PATIENTS AND METHODS: We collected data from 7 national NEN registries (Belgium, Czech Republic, Germany, Greece, Poland, Spain, Switzerland), representing 10,102 patients. Anonymised/pseudonymised data were collected in a secured server. Descriptive statistical methods were applied, as well as Kaplan-Meier survival curves and multivariable analyses for prognostic factors of overall survival (OS). RESULTS: median age of the study population was 60 years (range: 18-102), 48% were female. Common primary tumour sites were pancreas (27%) and small intestine (21%). Stage 4 disease was found in 47% of patients, while 26/10/16% had stage 1/2/3 disease, respectively. Grading (n = 6952) was G1/2/3 in 48/37/15% of the patients, respectively. Surgery was the main treatment, provided to 71% of patients, followed by somatostatin analogues (32%), chemotherapy (20%), Peptide receptor Radionuclide Therapy (PRRT) (9%) and targeted therapies (8%). OS at 5 years was 74%, influenced by grade, stage and tissue of origin in multivariate analysis. A Ki67 cut-off value set at 55% within the G3 group allowed to separate 2 groups with a meaningful different OS. CONCLUSION: We report the first analysis of the European Neuroendocrine Tumour Society registry, comprising 10,102 patients with NEN from 7 European countries. This large cohort study describes prognostic factors for the survival of NENs throughout Europe, including primary tumour site, grade, stage and treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018156
003      
CZ-PrNML
005      
20220804134605.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2022.03.007 $2 doi
035    __
$a (PubMed)35472579
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Borbath, Ivan $u Hepato-gastroenterology Unit, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. Electronic address: ivan.borbath@saintluc.uclouvain.be
245    14
$a The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms / $c I. Borbath, R. Garcia-Carbonero, D. Bikmukhametov, P. Jimenez-Fonseca, A. Castaño, J. Barkmanova, E. Sedlackova, A. Kollár, E. Christ, G. Kaltsas, B. Kos-Kudla, S. Maasberg, C. Verslype, UF. Pape
520    9_
$a BACKGROUND: Neuroendocrine neoplasms (NENs) are rare tumours with variable clinical behaviour. Their natural history is ideally best approached in large, multicentre and multinational registries with long-term patients' follow-up. The European Neuroendocrine Tumour Society registry aims to obtain information regarding NEN outcomes and prognostic factors in a European frame. PATIENTS AND METHODS: We collected data from 7 national NEN registries (Belgium, Czech Republic, Germany, Greece, Poland, Spain, Switzerland), representing 10,102 patients. Anonymised/pseudonymised data were collected in a secured server. Descriptive statistical methods were applied, as well as Kaplan-Meier survival curves and multivariable analyses for prognostic factors of overall survival (OS). RESULTS: median age of the study population was 60 years (range: 18-102), 48% were female. Common primary tumour sites were pancreas (27%) and small intestine (21%). Stage 4 disease was found in 47% of patients, while 26/10/16% had stage 1/2/3 disease, respectively. Grading (n = 6952) was G1/2/3 in 48/37/15% of the patients, respectively. Surgery was the main treatment, provided to 71% of patients, followed by somatostatin analogues (32%), chemotherapy (20%), Peptide receptor Radionuclide Therapy (PRRT) (9%) and targeted therapies (8%). OS at 5 years was 74%, influenced by grade, stage and tissue of origin in multivariate analysis. A Ki67 cut-off value set at 55% within the G3 group allowed to separate 2 groups with a meaningful different OS. CONCLUSION: We report the first analysis of the European Neuroendocrine Tumour Society registry, comprising 10,102 patients with NEN from 7 European countries. This large cohort study describes prognostic factors for the survival of NENs throughout Europe, including primary tumour site, grade, stage and treatment.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a neuroendokrinní nádory $x patologie $7 D018358
650    12
$a nádory slinivky břišní $x patologie $7 D010190
650    _2
$a prognóza $7 D011379
650    12
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a somatostatin $7 D013004
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Garcia-Carbonero, Rocio $u Oncology Department, Hospital Universitario 12 de Octubre, IIS Imas12, UCM, CNIO, CIBERONC, Madrid, Spain. Electronic address: rgcarbonero@gmail.com
700    1_
$a Bikmukhametov, Damir $u Charité University Hospital Berlin, Gastroenterology Department, Berlin, Germany. Electronic address: damirbikm@gmail.com
700    1_
$a Jimenez-Fonseca, Paula $u Hospital Universitario Central de Asturias, Medical Oncology, Oviedo, Asturias, Spain. Electronic address: palucaji@hotmail.com
700    1_
$a Castaño, Angel $u Hospital Universitario de Fuenlabrada, Pathology Unit, Madrid, Spain. Electronic address: angel.castano@salud.madrid.org
700    1_
$a Barkmanova, Jaroslava $u Charles University, Oncological Clinic, General Faculty Hospital and 1.st Medical Faculty, Praha, Czech Republic. Electronic address: jaroslava.barkmanova@vfn.cz
700    1_
$a Sedlackova, Eva $u Charles University, Oncological Clinic, General Faculty Hospital and 1.st Medical Faculty, Praha, Czech Republic. Electronic address: eva.sedlackova@vfn.cz
700    1_
$a Kollár, Attila $u Department of Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: attila.kollar@insel.ch
700    1_
$a Christ, Emanuel $u Universitätsspital Basel, Endocrinology, Diabetology and Metabolism, Basel, Switzerland. Electronic address: emanuel.christ@usb.ch
700    1_
$a Kaltsas, Gregory $u National and Kapodistrian University of Athens, Department of General Medicine and Endocrinology, Athens, Attica, Greece. Electronic address: gregory.kaltsas@gmail.com
700    1_
$a Kos-Kudla, Beata $u Medical University of Silesia, Department of Pathophysiology and Endocrinology, Katowice, Slaskie, Poland. Electronic address: beatakos@ka.onet.pl
700    1_
$a Maasberg, Sebastian $u Asklepios Kliniken Hamburg, Department of Internal Medicine and Gastroenterology, Hamburg, Germany. Electronic address: s.maasberg@asklepios.com
700    1_
$a Verslype, Chris $u Katholieke Universiteit Leuven, UZ Leuven, Digestive Oncology - Hepatology, Leuven, Belgium. Electronic address: chris.verslype@uzleuven.be
700    1_
$a Pape, Ulrich-Frank $u Asklepios Kliniken Hamburg, Department of Internal Medicine and Gastroenterology, Hamburg, Germany. Electronic address: ul.pape@asklepios.com
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 168, č. - (2022), s. 80-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35472579 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134559 $b ABA008
999    __
$a ok $b bmc $g 1821971 $s 1169399
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 168 $c - $d 80-90 $e 20220423 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options